JPH06510283A - ５−ｈｔ４レセプター拮抗薬 - Google Patents

５−ｈｔ４レセプター拮抗薬

Info

Publication number
JPH06510283A
JPH06510283A JP5504191A JP50419193A JPH06510283A JP H06510283 A JPH06510283 A JP H06510283A JP 5504191 A JP5504191 A JP 5504191A JP 50419193 A JP50419193 A JP 50419193A JP H06510283 A JPH06510283 A JP H06510283A
Authority
JP
Japan
Prior art keywords
butyl
acid
room temperature
water
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5504191A
Other languages
English (en)
Japanese (ja)
Inventor
キング，フランシス・デイビッド
ガスター，ララミー・メアリー
ジョイナー，グラハム・フランシス
ラーマン，シャーリー・キャサリン
サンガー，ガレス・ジョン
ウォードル，ケイ・アリソン
バクスター，ゴードン・スミス
ケネット，ガイ・アンソニー
ヤング，ロドニー・クリストファー
ヴィマール，ミシリー
カウマン，アルベルト・ジュリオ
Original Assignee
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919117943A external-priority patent/GB9117943D0/en
Priority claimed from GB919119692A external-priority patent/GB9119692D0/en
Priority claimed from GB929201414A external-priority patent/GB9201414D0/en
Priority claimed from GB929203977A external-priority patent/GB9203977D0/en
Priority claimed from GB929208321A external-priority patent/GB9208321D0/en
Application filed by スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー filed Critical スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー
Publication of JPH06510283A publication Critical patent/JPH06510283A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
JP5504191A 1991-08-20 1992-08-18 ５−ｈｔ４レセプター拮抗薬 Pending JPH06510283A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB9117943.2 1991-08-20
GB919117943A GB9117943D0 (en) 1991-08-20 1991-08-20 Medicaments
GB919119692A GB9119692D0 (en) 1991-09-14 1991-09-14 Pharmaceuticals
GB9119692.3 1991-09-14
GB929201414A GB9201414D0 (en) 1992-01-23 1992-01-23 Medicaments
GB9201414.1 1992-01-23
GB929203977A GB9203977D0 (en) 1992-02-25 1992-02-25 Pharmaceuticals
GB9203977.5 1992-02-25
GB9208321.1 1992-04-15
GB929208321A GB9208321D0 (en) 1992-04-15 1992-04-15 Pharmaceuticals
PCT/GB1992/001519 WO1993003725A1 (fr) 1991-08-20 1992-08-18 Antagonistes du recepteur 5-ht4

Publications (1)

Publication Number Publication Date
JPH06510283A true JPH06510283A (ja) 1994-11-17

Family

ID=27517068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5504191A Pending JPH06510283A (ja) 1991-08-20 1992-08-18 ５−ｈｔ４レセプター拮抗薬

Country Status (8)

Country Link
EP (1) EP0600955A1 (fr)
JP (1) JPH06510283A (fr)
AU (2) AU2435092A (fr)
CA (1) CA2116024A1 (fr)
MX (1) MX9204786A (fr)
NZ (1) NZ243993A (fr)
PT (1) PT100785A (fr)
WO (1) WO1993003725A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009513544A (ja) * 2003-07-18 2009-04-02 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 神経因性疼痛治療用インダゾール誘導体の使用方法
JP2016522215A (ja) * 2013-06-05 2016-07-28 ユニベルシテ ドゥ カーン ノルマンディ プロムネシア効果を有するアセチルコリンエステラーゼ抑制化合物と５ｈｔ４セロトニン作動性受容体作動薬の調製方法並びにその構成薬剤組成

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128172A1 (en) 1991-12-21 2002-09-12 Smithkline Beecham Plc Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
US5763459A (en) * 1992-05-23 1998-06-09 Smithkline Beecham P.L.C. Medicaments for the treatment of anxiety
AU4350493A (en) * 1992-06-27 1994-01-24 Smithkline Beecham Plc Medicaments containing 5-ht4 receptor antagonists
EP0664794A1 (fr) * 1992-10-16 1995-08-02 Smithkline Beecham Plc Esters/amides n-alkylpiperidinyl-4-methyl carboxyliques des systemes de cycles condenses en tant qu'inhibiteurs de recepteurs 5-ht4
ES2056728B1 (es) * 1992-10-28 1995-05-01 Smithkline Beecham Plc Nuevos derivados de piperidilo y aminoalquilo con actividad antagonista del receptor 5-ht4
US5705498A (en) * 1992-11-05 1998-01-06 Smithkline Beecham Plc. Piperidine derivatives as 5-HT4 receptor antagonists
US6127379A (en) * 1993-02-01 2000-10-03 Smithkline Beecham P.L.C. Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists
GB9310582D0 (en) * 1993-05-22 1993-07-07 Smithkline Beecham Plc Pharmaceuticals
GB9312348D0 (en) * 1993-06-16 1993-07-28 Smithkline Beecham Plc Pharmaceuticals
FR2717174B1 (fr) * 1994-03-14 1996-05-31 Sanofi Sa Utilisation de pipéridinoéthyl esters de l'acide 4-amino-5-chloro-2-méthoxybenzoïque comme 5-HT4 agonistes.
AU2075295A (en) * 1994-03-14 1995-10-03 Sanofi Use of 4-amino-5-chloro-2-methoxybenzoic esters as 5-ht4 agonists
EP0683161A1 (fr) * 1994-05-17 1995-11-22 MIDY S.p.A. Nouvel ester de l'acide 4-amino-5-chloro-2-méthoxybenzoique, procédé pour sa préparation et compositions pharmaceutiques le contenant
WO1996005166A1 (fr) * 1994-08-11 1996-02-22 Yamanouchi Pharmaceutical Co., Ltd. Derive d'amine substitue et composition medicamenteuse le contenant
DE69508600T2 (de) * 1994-09-27 1999-11-25 Janssen Pharmaceutica Nv Phenyl-oxo-alkyl-(4-piperidinyl) benzoatderivate
WO1996010027A1 (fr) * 1994-09-27 1996-04-04 Janssen Pharmaceutica N.V. Derives benzoates bicycliques de piperidinyle n-substitue
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
DE69627323T2 (de) * 1995-05-31 2004-01-15 Nisshin Seifun Group Inc Indazolderivate mit einer cyclischen aminogruppe
AU707325B2 (en) * 1995-11-09 1999-07-08 Sanofi-Aventis 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one derivatives for use as 5-HT4 or H3 receptor ligands
FR2741069B1 (fr) * 1995-11-09 1997-12-12 Synthelabo Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
TW445263B (en) 1996-02-29 2001-07-11 Janssen Pharmaceutica Nv Novel esters of 1,4-disubstituted piperidine derivatives
IT1291569B1 (it) * 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
TW548103B (en) 1997-07-11 2003-08-21 Janssen Pharmaceutica Nv Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
FR2766484B1 (fr) * 1997-07-25 1999-09-17 Logeais Labor Jacques Nouveaux derives benzamides stimulants de la motricite gastrointestinale haute et basse
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
JP3366323B2 (ja) * 1998-09-10 2003-01-14 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ４受容体アンタゴニストとしてのジヒドロベンゾジオキシンカルボキサミド及びケトン誘導体
AU763960B2 (en) * 1998-11-20 2003-08-07 F. Hoffmann-La Roche Ag Pyrrolidine derivatives-CCR-3 receptor antagonists
TW570920B (en) 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
FR2821356A1 (fr) 2001-02-23 2002-08-30 Cerep Nouveaux derives d'arylcarbamates et d'arylurees, preparations et utilisations
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
ES2332808T3 (es) 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
EP1807423B1 (fr) 2004-11-05 2009-05-20 Theravance, Inc. Composes de quinolinone-carboxamide
NZ555180A (en) 2004-12-22 2010-09-30 Theravance Inc Indazole-carboxamide compounds useful as 5-HT4 receptor agonists
EP1871772B1 (fr) 2005-03-02 2014-09-10 Theravance, Inc. Composes de quinolinone en tant qu'agonistes des recepteurs de 5-ht4
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531083B1 (fr) * 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
EP0189002B1 (fr) * 1984-12-20 1993-03-03 Sandoz Ag Traitement de maladies gastro-intestinales utilisant des 5-HT3 antagonistes
DE3650772T2 (de) * 1985-04-27 2003-04-03 Hoffmann La Roche Derivate von Indazole-3-carboxamide und -3-carboxylsäure
CA2030051C (fr) * 1989-11-17 2001-08-07 Haruhiko Kikuchi Derives indole

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009513544A (ja) * 2003-07-18 2009-04-02 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 神経因性疼痛治療用インダゾール誘導体の使用方法
JP2016522215A (ja) * 2013-06-05 2016-07-28 ユニベルシテ ドゥ カーン ノルマンディ プロムネシア効果を有するアセチルコリンエステラーゼ抑制化合物と５ｈｔ４セロトニン作動性受容体作動薬の調製方法並びにその構成薬剤組成

Also Published As

Publication number Publication date
PT100785A (pt) 1994-04-29
WO1993003725A1 (fr) 1993-03-04
MX9204786A (es) 1993-04-01
NZ243993A (en) 1994-10-26
AU5194496A (en) 1996-07-18
EP0600955A1 (fr) 1994-06-15
CA2116024A1 (fr) 1993-03-04
AU2435092A (en) 1993-03-16

Similar Documents

Publication Publication Date Title
JPH06510283A (ja) ５−ｈｔ４レセプター拮抗薬
FI107158B (fi) Menetelmä kondensoitujen indolikarboksylaatti- ja indolikarboksiamidijohdannaisten valmistamiseksi
JP3294611B2 (ja) ５−ｈｔ４レセプター・アンタゴニスト
EP0764163B1 (fr) Antagonistes du recepteur de la tachykinine (nk 1)
RU2351588C2 (ru) Производные n-фенил(пиперидин-2-ил)метил-бензамида и их применение в терапии
US5942536A (en) N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists
US20040220193A1 (en) Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound
JPH06509574A (ja) ５−ｈｔ↓４レセプターアンタゴニスト
SK280906B6 (sk) Použitie tetrahydrokarbazolových derivátov
EP0343900A2 (fr) Composés pipéraziniques
ES2277330T3 (es) Antagonistas del receptor 5-ht4.
GB2266888A (en) Tetramic acid derivatives
KR20040094872A (ko) ５-ｈｔ１ｆ 효능제로서의 피리디노일피페리딘
JP5588018B2 (ja) α４β２神経性ニコチン性アセチルコリン受容体リガンド
JPH08508738A (ja) ５−ｈｔ１ａ及び／又は５−ｈｔ２リガンドとしてのインドール誘導体
JP2006523692A (ja) ５−ｈｔ１ｆ作用薬としての（ピペリジニルオキシ）フェニル、（ピペリジニルオキシ）ピリジニル、（ピペリジニルスルファニル）フェニル、および（ピペリジニルスルファニル）ピリジニル化合物
EA011635B1 (ru) Новые производные амида гетероциклической карбоновой кислоты
JP2008509151A (ja) ２，８−二置換ナフチリジン誘導体
WO1998055115A1 (fr) Carboxamides utilises comme agonistes de 5-ht¿1f?
JPH08502283A (ja) ５−ｈｔ▲下４▼レセプターアンタゴニスト用の縮合環系ｎ−アルキルピペリジニル−４−メチルカルボン酸エステル／アミド
JPH10500698A (ja) カルシウムチャンネルアンタゴニストとしてのフェノキシアルキル置換ピペリジン、ピロリジン、モルホリンおよびチオモルホリン
CA2179678A1 (fr) Derives de substitution en 6 de 1,2,3,4-tetrahydro-9h-carbazole et de derives de substitution en 7 de 10h-cyclohepta¬7,6-b|indole
JPH07133273A (ja) 光学活性イミダゾリジノン誘導体とその製造方法
CZ335495A3 (en) N-substituted azaheterocyclic carboxylic acids and their esters, process of their preparation and pharmaceutical compositions containing thereof
JPH0386865A (ja) 置換キノリン誘導体